Free shipping on all orders over $ 500

TVB-3664

Cat. No. M10175
TVB-3664 Structure
Synonym:

TVB3664

Size Price Availability Quantity
2mg USD 240  USD240 In stock
5mg USD 400  USD400 In stock
10mg USD 690  USD690 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

TVB-3664 is a FASN inhibitor which significantly reduces tubulin palmitoylation and mRNA expression. TVB-3664 combined with taxane treatment enhances inhibition of in vitro tumor cell growth compared to treatmentwith either agent alone. In lung, ovarian, prostate, and pancreatic tumor xenograft studies, TVB-3664 and paclitaxel or docetaxel combine to inhibit xenograft tumor growth with significantly enhanced anti-tumor activity.

Protocol (for reference only)
Cell Experiment
Cell lines Calu-6 cells, A549 cells
Preparation method Calu-6 cells are treated with 50 nM TVB-3664 for 48 h. Paclitaxel is added to the cell culture media to a final concentration of 6 nM. After the 2 h of incubation with paclitaxel, cells and supernatant are collected for analysis.
Concentrations 50 nM
Incubation time 48 h, 72 h
Animal Experiment
Animal models female BALB-c-nude mice
Formulation formulated at 3-V Biosciences in 100% PEG-400 and diluted with water to a final PEG concentration of 30% immediately before dosing for oral dosing
Dosages 10 mg/kg, 2.5 mg/kg
Administration PO, IV
Chemical Information
Molecular Weight 468.47
Formula C25H23F3N4O2
CAS Number 2097262-58-1
Solubility (25°C) DMSO 85 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Yekaterina Y Zaytseva, et al. Oncotarget. Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer

[2] Timothy S Heuer, et al. EBioMedicine. FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression

Related FAS Products
GSK837149A 

GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (Ki=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer.

IPI-9119

IPI-9119 is an orally active, selective and irreversible Fatty Acid Synthase (FASN) inhibitor, with an IC50 of 0.3 nM.

Eicosapentaenoic acid ethyl ester

Eicosapentaenoic acid ethyl ester (AMR101, EPA ethyl ester, Ethyl eicosapentaenoate) is an omega-3 fatty acid agent that significantly reduces the triglyceride (TG) levels and improves other lipid parameters without significantly increasing the low-density lipoprotein (LDL) cholesterol levels.

FT113

FT113 is a potent inhibitor of fatty acid synthase(FASN) with ic50 of 213 nM.

PF429242 dihydrochloride

PF429242 dihydrochloride is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC50 of 175 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: TVB-3664, TVB3664 supplier, FAS, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.